Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor

17. november 2026 oppdatert av: AbbVie

A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults

Upper limb essential tremor (UL ET) is a movement disorder characterized by postural and/or kinetic tremor. It can cause difficulty with everyday tasks such as writing, pouring, and eating. This study will assess if AGN-151607-DP is safe and effective by assessing adverse events and change in disease activity in adult participants with UL ET.

AGN-151607-DP is an investigational drug being developed to treat UL ET. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 94 adult participants with upper limb essential tremor will be enrolled in approximately 40 sites in the United States/Canada.

Participants will receive intramuscular injections of AGN-151607-DP or matching placebo. Duration of the study is approximately 72 weeks.

The effect of the treatment will be checked by completion of questionnaires and side effects will be monitored by medical assessments.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

94

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3S 1N2
        • Rekruttering
        • True North Clinical Research /ID# 277130
    • Quebec
      • Lévis, Quebec, Canada, G6W 0M5
        • Rekruttering
        • Centre de Recherche St-Louis /ID# 277106
      • Pointe-Claire, Quebec, Canada, H9R 4Y2
        • Rekruttering
        • Genge Partners /ID# 277096
    • California
      • Carlsbad, California, Forente stater, 92011
        • Rekruttering
        • The Neurology Center of Southern California - Carlsbad /ID# 278194
      • Fresno, California, Forente stater, 93710
        • Rekruttering
        • Neuro Pain Research Center /ID# 277899
      • Fullerton, California, Forente stater, 92835
        • Rekruttering
        • Neurology Center Of North Orange County /ID# 278490
    • Connecticut
      • Stamford, Connecticut, Forente stater, 06905
        • Rekruttering
        • New England Institute for Clinical Research /ID# 277315
    • Florida
      • Boca Raton, Florida, Forente stater, 33486
        • Rekruttering
        • Parkinson'S Disease & Movement Disorders Center Of Boca Raton /ID# 277079
      • Orlando, Florida, Forente stater, 32803-1839
        • Rekruttering
        • Charter Research - Winter Park /ID# 277875
      • Pensacola, Florida, Forente stater, 32504-8649
        • Rekruttering
        • Emerald Coast Neurology /ID# 277898
    • Kansas
      • Overland Park, Kansas, Forente stater, 66211-1358
        • Rekruttering
        • Kansas Institute of Research /ID# 277068
    • New York
      • Amherst, New York, Forente stater, 14226
        • Rekruttering
        • Dent Neurologic Institute - Amherst /ID# 277242
      • Commack, New York, Forente stater, 11725
        • Rekruttering
        • True North Neurology /ID# 278118
    • North Carolina
      • Winston-Salem, North Carolina, Forente stater, 27103
        • Rekruttering
        • Neurology - Triad /ID# 277088
    • Ohio
      • New Albany, Ohio, Forente stater, 43054
        • Rekruttering
        • Mount Carmel Health System /ID# 278234
    • Tennessee
      • Memphis, Tennessee, Forente stater, 38157
        • Rekruttering
        • Veracity Neuroscience /ID# 277081
    • Texas
      • Dallas, Texas, Forente stater, 75206-5202
        • Rekruttering
        • Texas Neurology /ID# 277067
      • Frisco, Texas, Forente stater, 75035
        • Rekruttering
        • Lone Star Neurology /ID# 278266
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Houston Methodist Hospital /ID# 277326
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • Rekruttering
        • University of Virginia /ID# 278191
    • Washington
      • Spokane, Washington, Forente stater, 99202
        • Rekruttering
        • Inland Northwest Research /ID# 277077
    • Wisconsin
      • Greenfield, Wisconsin, Forente stater, 53228
        • Rekruttering
        • Center For Neurological Disorders /ID# 277048

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Minimum body weight of 50 kg (110 pounds) at Screening.

  • Diagnosis of essential tremor (ET) in accordance with the modified Tremor Research Investigation Group (TRIG) criteria, as follows:

    • Bilateral postural tremor with or without kinetic tremor, involving hands and forearms
    • Tremor of other body parts may or may not be present in addition to upper limb (UL) tremor
    • Bilateral tremor may or may not be asymmetric
    • Tremor that is reported by the participant to be persistent, although the amplitude may fluctuate.

Exclusion Criteria:

  • History of any medical condition that may put the participant at increased risk with exposure to purified botulinum toxin type A complex, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease that might interfere with neuromuscular junctional disorders.
  • History of an allergic reaction to or significant sensitivity to AGN-151607-DP or its excipients and/or other botulinum toxins.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: AGN-151607-DP

Participants will receive AGN-151607-DP.

Intramuscular Injection

Placebo komparator: Placebo for AGN-151607-DP

Participants will receive Placebo for AGN-151607-DP.

Intramuscular Injection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in The Essential Tremor Rating Assessment Scale (TETRAS)
Tidsramme: 72 weeks

TETRAS assesses participants' ability to function. Items are rated on a 5-category response scale from 0 (no tremor) to 4 (severe tremor).

72 weeks
Number of Participants with Adverse Events (AEs)
Tidsramme: 72 weeks

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

72 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change From Baseline in The Essential Tremor Rating Assessment Scale - Upper Limb (TETRAS-UL)
Tidsramme: 72 weeks

TETRAS Upper Limb (UL) Scale is an item of the TETRAS performance subscale that is designed to assess upper limb tremor. Items are scored from 0 to 4, with 0 indicating no tremor and 4 indicating a severe tremor.

72 weeks
Change From Baseline in Clinical Global Impression of Severity (CGIS)
Tidsramme: 72 weeks

CGI-S is a single item used to measure the clinician's impression of the current severity of the patient's essential tremor. The measure uses a 5-point rating scale with scores ranging none to very severe.

72 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: ABBVIE INC., AbbVie

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

23. juni 2026

Primær fullføring (Antatt)

1. november 2028

Studiet fullført (Antatt)

1. november 2028

Datoer for studieregistrering

Først innsendt

23. juni 2026

Først innsendt som oppfylte QC-kriteriene

23. juni 2026

Først lagt ut (Faktiske)

29. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • M25-850

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Tilgangskriterier for IPD-deling

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere